The 2060 Longevity Forum

This burgeoning anti-aging and longevity sector is poised for explosive growth, with a projected market value of $367 billion by 2032, driven by a compound annual growth rate of 30+%, according to Research & Markets.

Backed by billionaires and institutional investors, the industry is spearheaded by trailblazers conducting groundbreaking research aimed at halting aging and, perhaps, rewriting the very concept of mortality. Visionaries such as Jeff Bezos, Peter Thiel, Larry Ellison, and Larry Page, along with companies like Alphabet, are pouring resources into a field where science meets ambition.

At the forefront of this movement are organizations like the Methuselah Foundation, Juvenescence and BioSplice Therapeutics, exploring solutions from cellular reprogramming and gene therapy to cyborg technology and regenerative medicine. With approaches like cryonics, mind uploading, and young-blood transfusions, these pioneers are redefining possibilities. As big names and investments converge, the longevity revolution marks a new era in human potential.

In 2009, Japanese scientist Yamanaka discovered the OSKM factors, genes that can rejuvenate cells to a youthful state. This breakthrough earned him the Nobel Prize in 2012 and spurred significant advancements in cellular reprogramming .

This discovery, together with other promising technologies (cryopreservation, organ replacement, xenotransplantation, 3D organ printing, gene therapies, etc..) brought us closer than ever to defeating aging.

The pace of biotechnology and preventative medicine is being accelerated even more by Artificial Intelligence. Currently, many ongoing R&D projects address the topic of massively parallel "in silico" drug discovery, some of them reliably testing 1 billion molecules / day.